哈密如何治霉菌性阴道炎(哈密哪个季节适合做包皮手术) (今日更新中)

The damage wrought by Hurricane Irma has sparked a fresh wave of giving from corporate America.The extent of the destruction in Florida and the Caribbean isn't yet known, and Irma is still making its way toward Georgia as a tropical storm. It could be one of the costliest natural disasters in U.S. history.Corporate donations raised in the immediate aftermath of Hurricane Harvey, which struck two weeks ago, totaled about 0 million.A fundraising effort called Hand in Hand, backed by Verizon, Apple and other major companies, is hosting a televised fundraiser on Tuesday at 8 p.m. ET. Beyoncé and Oprah Winfrey are among the celebrities who have signed on.Here is a running list of all the ways companies have promised to help, both for Harvey and Irma relief.Apple: Donated million to the Red Cross in addition to pledging million for the Hand in Hand effort.Ashley Furniture: Promised to contribute products and subsidize furniture purchases up to million for hurricane victims in Texas and Florida.AT&T: Donating .4 million to relief efforts in the Caribbean and U.S. states hurt by Harvey and Irma. The company previously announced it would contribute at least 0,000 to help communities after Harvey.Bank of America: Donating more than .5 million to victims of the two storms, including 4,000 donated by bank employees, which the company matched.Citi: In the wake of Irma, the Citi Foundation committed a million donation to the Red Cross, bringing its total hurricane relief contributions to million.Dick's Sporting Goods: The company and its foundation have pledged a combined .5 million to hurricane relief. That includes .5 million worth of clothing and footwear and million "to rebuild and refurbish youth sports programs and facilities" in affected areas.Discover: Pledging million to American Red Cross. The company is also matching up to million in donations to the American Red Cross by its card members.Disney: Pledging .5 million in humanitarian aid for Florida, the Caribbean and other places hit by Irma. Says it raised almost million for Harvey relief.Goldman Sachs: Committed to giving 0,000 to organizations involved in the "immediate search, clean-up and recovery efforts" after Harvey struck the Gulf Coast. After Irma, the company promised 0,000 more.Home Depot: Pledged million for Harvey and Irma relief.Humana: Says its Humana Foundation will donate million to the Red Cross for Irma relief.IBM: Has pledged million. It says million will go toward Harvey relief and million toward helping Irma victims.JPMorgan Chase: Says it will donate million to support Irma relief in the U.S. and the Caribbean. Funding goes to the Red Cross, International Medical Corps and local nonprofits. Also donated million to Harvey relief.Lowe's: Committed to million for Irma relief in cash and "product donations," after donating another million for Harvey relief.Panda Express: Committed to raising million in stores and donating million.PayPal: A sponsor of Hand in Hand, PayPal is donating 0,000 to Save the Children and 0,000 more to the Red Cross for Irma relief. It's also launching a campaign to raise money from donors. A similar campaign for Harvey relief raised more than million from 81,000 donors.Qualcomm: Says it gave million to the Center for Disaster Philanthropy. Qualcomm gave million more to various disaster relief organizations after Harvey struck Texas.Target: Pledged up to million to Irma relief organizations, including the Red Cross, Habitat for Humanity, the Salvation Army, UNICEF and Save the Children. This is in addition to a .5 million donation for Harvey relief.UnitedHealthcare: Announced a donation of million for Irma relief, and also a 2-to-1 match for employee donations. It previously promised .3 million in "cash and medicines" after Harvey.Verizon: After announcing a million commitment after Harvey, Verizon said it would donate .5 million to Hand in Hand.Walmart: Has committed to donating up to million to hurricane relief.Wells Fargo: Pledged .1 million to Irma relief efforts in Florida and the Caribbean, nearly half to the Red Cross. The company said its customers have donated, via ATMs, nearly .7 million to the Red Cross for Harvey relief. 4337

The boy who made headlines when he was photographed hugging an officer during a 2014 protest against police brutality is missing after his family's SUV plunged 100 feet off a coastal highway in California, officials said Wednesday.The bodies of Jennifer and Sarah Hart, of Washington, and three of their six children, were found Monday in and around the vehicle, which landed on its roof in the Pacific Ocean, Mendocino County Sheriff Tom Allman said. Their three other children, including 15-year-old Devonte, are missing. 531

The city attorney is cracking down on independent living facilities that are posing a danger to their residents - and potentially neighbors.City Attorney Mara Elliott's office is investigating about two-dozen of these facilities and prosecuting the operators of six, the office announced Wednesday. The facilities, often inside single-family homes, are unregulated and unlicensed. They provide physically and mentally disabled persons a last chance to avoid homelessness. But Elliott said the operators often take advantage of residents. She said this came onto her radar after investigating a home last year. "It was a horrible situation where 11 individuals were essentially being held captive in this home and didn't have sanitary facilities," she said. "The shower facilities were covered in feces, they didn't have food they didn't have ventilation, they didn't have access to telephones."On Wednesday, Elliott's office announced charges against two more facilities, one on Parkbrook Lane in Skyline and another on Brandywood Street in North Bay Terraces. Operators and owners are charged with violations including vermin infestations, blocked exists, improper plumbing, and fire hazards. People who live near the Parkbrook Lane home described shouting in the middle of the night, verbal harassment, physical fighting and graffiti. "We moved because of it," said one neighbor, whose first name was Tammy. The home had trash and old mattresses on the property. The owner, Evelyn Louise Peters, said the issues identified were only one-time instances and the trash accumulated after the home was vacated. Sherry Lynn Bennett, who manages the home in North Bay Terraces, said the issues are being dealt with."The owners have been doing all the repairs, everything is done, everything's back to normal, we've done everything the city's said," Bennett said. Bennett and Peters are charged with 22 misdemeanor violations of the health, safety and municipal codes.There is no telling how many of these facilities exist in the county. In December, a man living in an El Cajon independent living home was beaten to death with a frying pan. El Cajon police had responded to calls at the home 78 times in the year leading up to the event. 2241

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The doors to Interior Secretary Ryan Zinke's office are getting a nearly 9,000 upgrade.The Interior Department confirmed the project Thursday, saying it is both necessary to replace old doors that are in "disrepair" and attributing the high cost to the historical nature of the building.News of the 8,670 contract comes as several agencies are facing scrutiny over excessive spending. Last month, Housing and Urban Development Secretary Ben Carson withdrew an order for pricey dining room furniture, including a ,000 table. Zinke is also under fire for questionable travel habits.Zinke was unaware of the expense for the doors, Interior spokeswoman Heather Swift said, saying the project was driven by "career facilities and security officials" as part of a decade-long modernization of the 1930s building."The secretary was not aware of this contract but agrees that this is a lot of money for demo, install, materials, and labor," Swift said in a statement. "Between regulations that require historic preservation and outdated government procurement rules, the costs for everything from pencils to printing to doors is astronomical. This is a perfect example of why the secretary believes we need to reform procurement processes."The new doors will be made of fiberglass. The previous sets of doors have been damaged for years, according to an Interior official, to the point where wind and water come into the office during inclement weather, which in turn damaged the historic hardwood floors. Damage has caused bottom panels to fall out and be "replaced with cardboard and duct tape," the official said.The Associated Press previously reported on the door contract Thursday."What a waste. Just think how many dining sets you could have bought or private jets you could have chartered with that money," Rep. Adam Schiff, D-California, joked on Twitter. 1898

来源：资阳报